Published

Psilocin mediates long-term synaptic depression in the prelimbic cortex through 5-HT2A receptor-independent mechanisms

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Neuropharmacology
Date: 2026-05-01
Source: Crossref
DOI: 10.1016/j.neuropharm.2026.110854
PubMed: 41577180

Authors

Domi Ana Lucente Erika Cadeddu Davide Bengtsson Niklas Smedler Erik Adermark Louise

Watch author

Derived topics and classifications

psilocin Depression Neuroplasticity Mechanism of Action Receptor Pharmacology Other

Citation graph

40 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

10.1038/s41386-021-01232-x 10.3390/ijms25010581 10.1016/s0028-3908(97)00051-8 10.1016/s0006-8993(99)01224-x 10.1101/lm.6.3.216 10.1016/0306-4522(91)90128-b 10.1093/cercor/bhy064 10.1001/jamapsychiatry.2022.2096 10.1016/j.tins.2024.08.011 10.1017/s1461145712000466 10.1056/nejmoa2032994 10.1073/pnas.1119598109

Indexed papers citing this DOI

Psilocin mediates long-term synaptic depression in the prelimbic cortex through 5-HT2A receptor-independent mechanisms2026-05-01

Related papers

Phase 1, Open-Label, One-Treatment, Single-Dose, One-Period, Pharmacokinetic Study of Psilocin 4 mg as Its Mucic Acid Salt (L-130) Form, in Healthy Subjects Under Fasted ConditionsClinicalTrials.gov · 2023-09-13 A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.ClinicalTrials.gov · 2026-03-03 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-Assisted Psychotherapy in Treating Severe Depression Among Adults With Post-Traumatic Stress Disorder (PTSD).ClinicalTrials.gov · 2023-11-29 A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 (psilocybin) in Healthy ParticipantsClinicalTrials.gov · 2024-10-09